A Dose-escalation Study of R1507 in Patients With Advanced Solid Tumors.
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Neoplasms
Both
Neoplasms
Trial Information
A Dose-escalation Study of R1507 in Patients With Advanced Solid Tumors.
Inclusion Criteria:
- adult patients, >=18 years of age;
- solid neoplasm, non-Hodgkin's lymphoma or Hodgkin's lymphoma;
- metastatic or locally advanced disease, not curable by any currently available
treatment.
Exclusion Criteria:
- severe, uncontrolled systemic disease;
- patients who require treatment with glucocorticoids or immunosuppressive treatment
within last 6 months;
- patients with diabetes mellitus.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
AEs, laboratory parameters, Cmax, Tmax, AUC, clearance, Vdss elimination half life
Outcome Time Frame:
Throughout study
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
United States: Food and Drug Administration
Study ID:
BO19373
NCT ID:
NCT00400361
Start Date:
April 2006
Completion Date:
April 2011
Related Keywords:
- Neoplasms
- Neoplasms
Name | Location |
|---|---|
| Austin, Texas 78705 | |
| Hackensack, New Jersey 07601 | |
| Denver, Colorado |
